Skip to content

TAmoxifen Versus LIdocaine Cream. A Randomized Clinical Trial for Reducing Pain and Discomfort During Mammography

Randomized Study of the Use of Tamoxifen Versus Ointment Lidocaine for Reducing the Pain and Discomfort in Mammography

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02801786
Acronym
TALI
Enrollment
450
Registered
2016-06-16
Start date
2018-11-30
Completion date
2021-06-30
Last updated
2018-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Discomfort, Pain

Keywords

Mammography, Premedication, Pain, Discomfort, Breast

Brief summary

This is a double-blind placebo-controlled randomized clinical trial to test the use of tamoxifen or lidocaine for diminishing the pain and discomfort while performing mammography, intending to include 450 patients distributed between the three groups.

Detailed description

This is a double-blind placebo-controlled randomized clinical trial to test the use of tamoxifen or lidocaine for diminishing the pain and discomfort while performing mammography, intending to include 450 patients distributed between the three groups. Inclusion criteria:Patients presenting mastalgia with a prior indication for mammography who is over 40 years old, undergoing their radiological examination at the university hospital of the Federal University of Goias. The only patients who were not included were those who did not wish to participate in the study. The patients will receive: * Group 1:Five capsules containing 20mg of tamoxifen plus one sachet containing gel placebo; * Group 2: Five capsules containing placebo and one sachet containing lidocaine gel at 4%; * Group 3: Five capsules containing placebo plus one sachet containing gel placebo. Mammography procedures: The mammography at the university hospital was carried out using a high-resolution mammograph with mean compression in each plane of approximately 800 newtons. All the patients will undergo at least four imaging views: one craniocaudal and one mediolateral oblique plane for each breast. When necessary, complementary imaging will be used, including selective compression, magnification or other methods. Control variables: * Patient's age in completed years at the time of the study; * Time within the menstrual cycle; * Menopausal status; * Use of oral contraceptives; * Use of hormone replacement therapy; * Previous history of mastalgia; * Number of cups of coffee drunk per day; * Bra size; * Weight and height, for body mass index (BMI): weight in kilograms and height in meters, according to information provided by the patient at the time of the study; * Any previous mammographic examination. Dependent variables: The pain will be used to measure according to the linear visual analog pain scale. Discomfort will be recorded into four possible categories according to the patient's opinion: no discomfort, uncomfortable, very uncomfortable or intolerable. Ethical matters: This study was approved by the Research Ethics Committee of the university hospital of the Federal University of Goias and it will be conducted in accordance with the ruling principles of the Helsinki Convention.

Interventions

DRUGPlacebo

The arm will be composed of 03 women who used placebo capsules and gel.

DRUGLidocaine

The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.

DRUGTamoxifen

The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.

Sponsors

Universidade Federal de Goias
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with mastalgia in the mastology program with age 40 who have indication for mammography.

Exclusion criteria

* Patients who do not wish to participate in the study * Patients who underwent prosthetic silicone implants * Patients who mammoplasty (breast reduction or mastopexy) were submitted * Pregnant women * Patients allergic to tamoxifen or to lidocaine, heart disease, or patients with a history deep vein thrombosis.

Design outcomes

Primary

MeasureTime frameDescription
Tamoxifen for pain during mammographyBetween review, test, randomization, application of results, data analysis and delivery of results for publication will be 24 months.An additional 15% of patients who did not experience pain during mammography using the medication.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026